Tong Zhang

Dr. Tong Zhang

Genome Institute of Singapore, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2018 in Nature
Verified
Journal Article
Closed access
PDF file
YSYannick Simoni
Yannick Simoni
EBEtienne Becht
Etienne Becht
MFMichael Fehlings
Michael Fehlings
CLChiew Yee Loh
Chiew Yee Loh
SKSi-Lin Koo
Si-Lin Koo
ENEvan W. Newell
Evan W. Newell

19 March 2015 in Chemical Reviews
Verified
Journal Article
Closed access
JNJessica Nasica-Labouze
Jessica Nasica-Labouze
PNPhuong H. Nguyen
Phuong H. Nguyen
FSFabio Sterpone
Fabio Sterpone
OBOlivia Berthoumieu
Olivia Berthoumieu
NBNicolae-Viorel Buchete
Nicolae-Viorel Buchete
PDPhilippe Derreumaux
Philippe Derreumaux

1 May 2016 in Molecular Cell
Verified
Journal Article
Closed access
JAJong Ghut Ashley Aw
Jong Ghut Ashley Aw
YSYang Shen
Yang Shen
AWAndreas Wilm
Andreas Wilm
MSMiao Sun
Miao Sun
XLXin Ni Lim
Xin Ni Lim
YWYue Wan
Yue Wan

9 April 2013 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
TZTong Zhang
Tong Zhang
JZJian Zhang
Jian Zhang
PDPhilippe Derreumaux
Philippe Derreumaux
Yuguang MuYuguang Mu
Yuguang Mu

15 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
RNRahul Nahar
Rahul Nahar
WZWeiwei Zhai
Weiwei Zhai
TZTong Zhang
Tong Zhang
ATAngela Takano
Angela Takano
AKAlexis J. Khng
Alexis J. Khng
DTDaniel S. W. Tan
Daniel S. W. Tan
EGFR-mutant lung adenocarcinomas (LUAD) display diverse clinical trajectories and are characterized by rapid but short-lived responses to EGFR tyrosine kinase inhibitors (TKIs). Through sequencing of 79 spatially distinct regions from 16 early stage tumors, we show that despite low mutation burdens, EGFR-mutant Asian LUADs unexpectedly exhibit a complex genomic landscape with frequent and early whole-genome doubling, aneuploidy, and high clonal diversity. Multiple truncal alterations, including TP53 mutations and loss of CDKN2A and RB1, converge on cell cycle dysregulation, with late sector-specific high-amplitude amplifications and deletions that potentially beget drug resistant clones. We highlight the association between genomic architecture and clinical phenotypes, such as co-occurring truncal drivers and primary TKI resistance. Through comparative analysis with published smoking-related LUAD, we postulate that the high intra-tumor heterogeneity observed in Asian EGFR-mutant LUAD may be contributed by an early dominant driver, genomic instability, and low background mutation rates.

27 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
WZWeiwei Zhai
Weiwei Zhai
TLTony Kiat-Hon Lim
Tony Kiat-Hon Lim
TZTong Zhang
Tong Zhang
SPSu-Ting Phang
Su-Ting Phang
ZTZenia Tiang
Zenia Tiang
ACand Pierce KH Chow
and Pierce KH Chow
Hepatocellular carcinoma (HCC) has one of the poorest survival rates among cancers. Using multi-regional sampling of nine resected HCC with different aetiologies, here we construct phylogenetic relationships of these sectors, showing diverse levels of genetic sharing, spanning early to late diversification. Unlike the variegated pattern found in colorectal cancers, a large proportion of HCC display a clear isolation-by-distance pattern where spatially closer sectors are genetically more similar. Two resected intra-hepatic metastases showed genetic divergence occurring before and after primary tumour diversification, respectively. Metastatic tumours had much higher variability than their primary tumours, suggesting that intra-hepatic metastasis is accompanied by rapid diversification at the distant location. The presence of co-existing mutations offers the possibility of drug repositioning for HCC treatment. Taken together, these insights into intra-tumour heterogeneity allow for a comprehensive understanding of the evolutionary trajectories of HCC and suggest novel avenues for personalized therapy.